Skip to main content
Caplight Logo









BOYDSense

BOYDSense

Private
ToulouseHealthcare & Life Scienceshttps://boydsense.com/

Last Round

Series A

Apr 5, 2024

Total Funding Raised

$11.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BOYDSense is a medical technology company that develops non-invasive health monitoring platforms using breath-based metabolomics to measure biomarkers for chronic disease management.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Sensors, Medical AI

Business Model

B2C

Customer Profile

Hardware Sales, Hardware + Subscription

AI Layer

Application

Keywords

non-invasive glucose monitoringbreath analyzerbreath-based metabolomicsneedle-free glucoseVOC biomarkerdiabetes managementmedical devicehealth IoTcontinuous glucose monitoringCGMdigital healthmedical AIremote patient monitoringRPMvolatile organic compoundVOC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BOYDSense Comparables

Compare BOYDSense with similar companies based on industry and business-model similarity.

BOYDSense comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DiaMonTech AG
85%
PKvitality
84%
Afon Technology
84%

BOYDSense Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 5, 2024
GrantDec 16, 2021

Key People

Founding team and executive leadership

Bruno Thuillier

Founder & CTO BOYDSense CEO BOYDSense, Inc.

Founding Team

BOYDSense Investors

Notable investors and investment history

BOYDSense investors
InvestorRounds
European Innovation Council FundGrant
Ambrosia InvestmentsConvertible Debt, Series A
Jolt CapitalConvertible Debt, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 59% MoM.

  • Apr 5, 2024

    $8M round led by diabetesfund and BioSerenity.

BOYDSense Filings

Explore SEC and related filing metadata, where available.

BOYDSense filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BOYDSense's valuation, stock price, and market status.

Is BOYDSense a public or private company?

BOYDSense is a private company.

What is the current stock price of BOYDSense?

BOYDSense is a private company with no public stock price. No recent secondary market data is available.

How much is BOYDSense worth (valuation)?

Valuation information for BOYDSense is not publicly available.

Can I buy BOYDSense stock?

BOYDSense shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BOYDSense's last funding round?

BOYDSense's most recent funding round was Series A on April 5, 2024.

Who are the main investors in BOYDSense?

Key investors in BOYDSense include European Innovation Council, Ambrosia Investments, Jolt Capital.

Will BOYDSense IPO soon?

No public IPO plans have been announced for BOYDSense.

How can I track BOYDSense secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BOYDSense's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersToulouse
Employee Range11
Year Founded2015
Last FundingApr 5, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?